Jefferies Trims MAOYAN ENT Target Price to HK$7.4, Forecasts Annual Box Office Decline

Stock News
03/30

Jefferies has adjusted its financial outlook for MAOYAN ENT (01896), lowering the target price from HK$9.6 to HK$7.4 while maintaining a "Buy" rating. The revision reflects recent business trends. For the 2025 fiscal year, the company reported total revenue of approximately RMB 4.6 billion, marking a year-on-year increase of about 13.5%, which aligns with prior guidance.

By segment, online entertainment ticketing revenue rose 19.4% to RMB 2.3 billion. Entertainment content services revenue grew 8.5% to around RMB 2.1 billion, while advertising services and other income increased 4.9% to RMB 210.7 million. Operating profit reached RMB 724.4 million, and net profit attributable to shareholders was RMB 563.1 million, both in line with expectations.

Management highlighted that despite weak box office performance during the Spring Festival, the industry's content supply requires time to adjust. Based on performance in the first three months, Jefferies anticipates a year-on-year decline in the overall box office for MAOYAN ENT in 2026.

Looking ahead, management identified three key opportunities for the industry: the shift toward more immersive content that is difficult to replicate, improved audience satisfaction due to better demand alignment and enhanced viewing experiences, and new growth avenues from emerging media formats, consumption scenarios, viewer preferences, and technological advancements.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10